Scarica l'app Stockscreener
585.48
2.42%
-14.52
Dopo l'orario di chiusura:
586.79
1.31
+0.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron Pharmaceuticals (REGN): Valuation in Focus Following Breakthrough Pipeline Results and Expanded Drug Approvals - simplywall.st
Strategies to average down on Regeneron Pharmaceuticals Inc.2025 Top Gainers & Smart Investment Allocation Tips - newser.com
Regeneron (REGN) Projects $83 Million R&D Charge in Q3 2025 - GuruFocus
Regeneron expects $83 million IPR&D charge in third quarter 2025 results - Investing.com
Top chart patterns to watch in Regeneron Pharmaceuticals Inc.Earnings Miss & Advanced Technical Signal Analysis - newser.com
Can trapped investors hope for a rebound in Regeneron Pharmaceuticals Inc.Earnings Summary Report & Weekly High Potential Alerts - newser.com
Is Regeneron Pharmaceuticals Inc. stock resilient to inflationQuarterly Market Review & Verified Technical Trade Signals - newser.com
111 Capital Makes New $517,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
J. Safra Sarasin Holding AG Sells 438 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Janney Montgomery Scott LLC Has $6.61 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Published on: 2025-10-06 01:04:19 - newser.com
Marietta Wealth Management LLC Has $6.01 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why pension funds invest in Regeneron Pharmaceuticals Inc. (RGO) stock2025 Support & Resistance & Daily Risk Controlled Trade Plans - newser.com
Applying Elliott Wave Theory to Regeneron Pharmaceuticals Inc.Weekly Stock Recap & Accurate Buy Signal Alerts - newser.com
Why millennials buy Regeneron Pharmaceuticals Inc. (RGO) stockRisk Management & Expert Approved Momentum Trade Ideas - newser.com
Why Regeneron (REGN) Is Up 6.4% After FDA Expansion and Positive Late-Stage Trial Results - simplywall.st
Mirae Asset Global Investments Co. Ltd. Grows Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Robeco Institutional Asset Management B.V. Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Truist Financial Corp Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals catalysts could drive stock higher: analysts - Proactive financial news
Forecasting Regeneron Pharmaceuticals Inc. price range with options data2025 Buyback Activity & Weekly Return Optimization Alerts - newser.com
Greenwood Capital Associates LLC Acquires 4,419 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Does Regeneron’s 8% Weekly Surge Signal a Shift After New FDA Drug Approval? - simplywall.st
Regeneron Pharmaceuticals, Inc. $REGN Stock Position Cut by Greenleaf Trust - MarketBeat
Applying chart zones and confluence areas to Regeneron Pharmaceuticals Inc.Analyst Downgrade & Fast Entry High Yield Stock Tips - newser.com
Feds Eye Partial Pretrial Ruling In Regeneron FCA Case - Law360
Regeneron (REGN) Highlights Benefits of Semaglutide and Trevogrumab in Obesity Management - Yahoo Finance
Formycon secures settlement and license agreement with Regeneron - The Pharma Letter
Regeneron Pharmaceuticals, Inc. (REGN) Draws Attention With Rare Disease Breakthrough - Insider Monkey
Q3 Earnings Forecast for REGN Issued By Leerink Partnrs - MarketBeat
Regeneron (REGN) Gets a Buy from Leerink Partners - The Globe and Mail
Hudson Value Partners LLC Acquires Shares of 759 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why Regeneron is giving away sequencing “for free”, with Alison Fenney - pharmaphorum
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron - MarketScreener
Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials - Yahoo Finance
The Best Biotech Stocks to Buy - Morningstar
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Up 6.9%Here's Why - MarketBeat
Red Biotechnology Market Size, Analysis, Trends | Leading - openPR.com
Leerink Partnrs Analysts Lower Earnings Estimates for REGN - MarketBeat
Generali Investments CEE investicni spolecnost a.s. Acquires 540 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
PGGM Investments Acquires 51,900 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron’s Evkeeza Receives FDA Approval to Treat HoFH in Children Aged 1 to Less Than 5 - Insider Monkey
What Makes Regeneron Pharmaceuticals (REGN) an Attractive Investment Opportunity? - MSN
Regeneron: Growth Catalysts Incoming (NASDAQ:REGN) - Seeking Alpha
Regeneron Pharmaceuticals, Inc. to Report Third Quarter 2025 Financial Results on October 28, 2025 - Quiver Quantitative
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025 - The Manila Times
Major Biotech Earnings Alert: Regeneron Pharmaceuticals Q3 2025 Results Coming October 28 Before Market Open - Stock Titan
Regeneron Sues Biosimilar Maker Over IP Rights Exemption - Law360
Regeneron Deal Clears Formycon’s Eylea Biosimilar for Late 2026 - Bloomberg Law News
Acute Gout Flare Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | Olatec Therapeutics, Dyve Biosciences, Changchun GeneScience Pharma, Regeneron Pharma, Novartis - Barchart.com
2 Beaten-Down Stocks to Buy and Hold for a Decade - Yahoo Finance
Tealwood Asset Management Inc. Buys 637 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Avior Wealth Management LLC Buys 581 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Inc RGO Stock Analysis and ForecastStock Buyback Announcements & Free Smart Stock Picking Tools - earlytimes.in
Can Regeneron Pharmaceuticals Inc. (RGO) stock deliver consistent EPS growth - newser.com
Regeneron (REGN) Gains Attention With Successful Phase 3 Garetosmab Trial for Rare Disease - Yahoo Finance
0.95%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):